Nasdaq:US$15.84 (+0.63) | HKEX:HK$24.80 (-0.30) | AIM:£2.35 (+0.04)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer